Dr. Budde is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Division of Lymphoma
1500 East Duarte Road
Duarte, CA 91010Phone+1 626-256-4673Fax+1 626-389-3058- Is this information wrong?
Education & Training
- University of WashingtonFellowship, Hematology and Medical Oncology, 2006 - 2009
- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2003 - 2006
- Duke UniversityPh.D., 1995 - 2001
- Tongji Medical UniversityClass of 1995
Certifications & Licensure
- CA State Medical License 2012 - 2024
- WA State Medical License 2006 - 2013
Awards, Honors, & Recognition
- Clinical investigator Damon runyon cancer research foundation
Clinical Trials
- Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Start of enrollment: 2007 Dec 01
- Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) Start of enrollment: 2013 Aug 01
- Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Start of enrollment: 2015 Dec 15
- Join now to see all
Publications & Presentations
PubMed
- Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma.James K Godfrey, Lei Gao, Geoffrey Shouse, Joo Y Song, Stacy Pak, Brian Lee, Bihong T Chen, Avyakta Kallam, John H Baird, Guido Marcucci, Lucy Y Ghoda, Stephanie Vaule...> ;Blood. 2024 Mar 14
- 1 citationsConsensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy.Crombie, J., Graff, T., Falchi, L., Karimi, Y., Bannerji, R., Nastoupil, L., Thieblemont, C., Ursu, R., Bartlett, N., Nachar, V., Weiss, J., Osterson, J., Patel, K., B...> ;Blood. 2024 Jan 22
- Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.Gregory, G., Kim, W., Hess, G., El-Sharkawi, D., Diefenbach, C., Huang, H., To, I., Parreira, J., Wu, M., Kwan, A., Assouline, S., Matasar, M., Bartlett, N., Shadman, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Dec 12
- Join now to see all
Abstracts/Posters
- Blinatumomab/Lenalidomide in Relapsed/Refractory Non-HodgkinÍs Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative AnalysisLihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, a...Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid LeukemiaLihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
- City of Hope Clinical and Laboratory Investigators Present New Research at the 60December 4th, 2018
- Mosunetuzumab plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed or Refractory Aggressive Large B Cell LymphomaDecember 23rd, 2023
Other Languages
- Chinese (Mandarin)
Hospital Affiliations
- City of Hope Comprehensive Cancer CenterDuarte, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: